Trials / Completed
CompletedNCT00454896
A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5mg and 10mg VESIcare® for the Treatment of Urgency Associated With Overactive Bladder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 739 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose is to evaluate the efficacy of 5 and 10mg VESIcare® (solifenacin succinate) in patients with urgency who have overactive bladder syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VESIcare® | Oral |
| DRUG | placebo | Oral |
Timeline
- Start date
- 2004-05-01
- Primary completion
- 2005-09-01
- Completion
- 2005-09-01
- First posted
- 2007-04-02
- Last updated
- 2014-09-18
Locations
65 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00454896. Inclusion in this directory is not an endorsement.